



吉林省輝南長龍生化藥業股份有限公司

Jilin Province Huinan Changlong Bio-pharmacy Company Limited

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 8049)

Interim Report 2025

CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE “STOCK EXCHANGE”)

GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration.

Given that the companies listed on GEM are generally small and mid-sized companies, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board of the Stock Exchange and no assurance is given that there will be a liquid market in the securities traded on GEM.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this report, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this report.

This report, for which the directors of Jilin Province Huinan Changlong Bio-pharmacy Company Limited (the “Directors”) collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM (the “GEM Listing Rules”) for the purpose of giving information with regard to Jilin Province Huinan Changlong Bio-pharmacy Company Limited and its subsidiary (“the Group”). The directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (1) the information contained in this report is accurate and complete in all material respects and not misleading; (2) there are no other matters the omission of which would make any statement in this report misleading; and (3) all opinions expressed in this report have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.

UNAUDITED INTERIM RESULTS

The directors of Jilin Province Huinan Changlong Bio-pharmacy Company Limited (“the Company”) are pleased to announce the unaudited consolidated financial statements of the Company and its subsidiaries (the “Group”) for the six months ended 30 June 2025 together with the comparative figures for the corresponding periods in 2024 as follows:

CONDENSED CONSOLIDATED INCOME STATEMENT (UNAUDITED)

For the six months ended 30 June 2025 and 30 June 2024

	Notes	Six months ended 30 June	
		2025 (Unaudited) RMB'000	2024 (Unaudited) RMB'000
Turnover	3	438,869	393,093
Cost of sales		(77,224)	(78,014)
Gross profit		361,645	315,079
Other revenue	3	9,771	30,116
Distribution and selling costs		(202,958)	(173,009)
Administrative expenses		(44,655)	(44,380)
Profit from operations	5	123,803	127,806
Finance costs		(941)	(813)
Profit before taxation		122,862	126,993
Taxation	6	(19,856)	(22,711)
Profit attributable to equity holders of the Company		103,006	104,282
Earnings per share			
– Basic	7	18.38 cents	18.61 cents
Dividends	8	–	–

Note: Calculation of the earnings per share in 2024 and 2025 was based on 560,250,000 shares and 560,250,000 shares respectively.

CONDENSED CONSOLIDATED BALANCE SHEET

As at 30 June 2025 and 31 December 2024

		30 June 2025 (Unaudited) RMB'000	31 December 2024 (Audited) RMB'000
	<i>Notes</i>		
Assets and liabilities			
Non-current assets			
Bearer biological assets	9	15,080	15,080
Property, plant and equipment	10	238,652	251,110
Investment properties		28,770	29,656
Right-of-use assets	11	46,881	46,881
Construction in progress	12	–	–
Intangible assets	13	13	17
Goodwill		6,254	6,254
Financial assets measured at amortised cost	18	949,037	1,048,737
Deferred tax assets		35,350	34,323
		1,320,037	1,432,058
Total non-current assets			
Current assets			
Inventories	14	87,175	59,971
Trade receivables	15	269,335	279,121
Contract assets		6,713	6,713
Other receivables, deposits and prepayments		216,793	214,213
Financial assets at fair value through profit or loss		53,265	93,265
Financial assets measured at amortised cost	18	209,919	209,919
Cash and cash equivalents		485,117	235,846
		1,328,317	1,099,048
Total current assets			

		30 June 2025 (Unaudited) RMB'000	31 December 2024 (Audited) RMB'000
	<i>Notes</i>		
Current liabilities			
Bank borrowings	16	72,000	72,000
Trade payables	17	66,064	63,541
Contract liabilities		21,240	21,240
Other payables and accruals		651,333	638,871
Deferred income		1,389	1,389
Income tax payable		3,655	3,613
Other tax payables		24,157	24,157
Loans from government authority		400	400
Dividend payable		35,049	35,458
		875,287	860,669
Total current liabilities		875,287	860,669
		453,030	238,379
Net current assets		453,030	238,379
		1,773,067	1,670,437
Total assets less current liabilities		1,773,067	1,670,437
Non-current liabilities			
Bank borrowings		-	-
Loan from government authority		3,934	3,934
Deferred income		34,954	34,954
Deferred tax liabilities		1,559	1,935
		40,447	40,823
		1,732,620	1,629,614
Net assets		1,732,620	1,629,614
Equity:			
Share capital	19	56,025	56,025
Reserves		1,676,595	1,573,589
Total equity		1,732,620	1,629,614

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (UNAUDITED)

For the six months ended 30 June 2025 and 30 June 2024

	PRC statutory funds				Total RMB'000
	Share capital RMB'000	Share premium RMB'000	Statutory surplus reserve RMB'000	Retained profits RMB'000	
At 1 January 2024 (Audited)	56,025	51,098	33,242	1,340,015	1,480,380
Net profit for the six months ended 30 June 2024 (Unaudited)	–	–	–	104,282	104,282
Dividends paid	–	–	–	–	–
At 30 June 2024 (Unaudited)	<u>56,025</u>	<u>51,098</u>	<u>33,242</u>	<u>1,444,297</u>	<u>1,584,662</u>
Net profit for the six months ended 31 December 2024 (Unaudited)	–	–	–	79,968	79,968
Dividends paid	–	–	–	(35,016)	(35,016)
Balance as at 31 December 2024 (Audited)	<u>56,025</u>	<u>51,098</u>	<u>33,242</u>	<u>1,489,249</u>	<u>1,629,614</u>
Net profit for the six months ended 30 June 2025 (Unaudited)	–	–	–	103,006	103,006
At 30 June 2025 (Unaudited)	<u>56,025</u>	<u>51,098</u>	<u>33,242</u>	<u>1,592,255</u>	<u>1,732,620</u>

NOTES TO CONDENSED INTERIM ACCOUNTS:

1. ORGANISATION AND OPERATIONS

The Company was established as a state-owned enterprise in the People's Republic of China (the "PRC") in 1989. On 29 December 1995, under the relevant provisions of the Company Law of the PRC, the Company was re-organized from a state-owned enterprise to a limited liability company. On 16 August 1996, with the approval of the Economic Restructuring Commission of Jilin Province, the Company was further converted into a joint stock limited company. On 20 April 1999, the Company made a bonus issue from capitalisation of retained profits at the proportion of one bonus share for every two existing shares. The Company's H shares were listed on the GEM of the Stock Exchange of Hong Kong Limited on 24 May 2001.

The Group is principally engaged in the manufacture and distribution of biochemical medicines in the PRC under the brand names of Changlong and Shendi.

2. BASIS OF PREPARATION OF FINANCIAL STATEMENTS

The unaudited condensed consolidated financial statements have been prepared in accordance with all applicable Hong Kong Financial Reporting Standards ("HKFRSs"), which collective term includes all applicable individual Hong Kong Financial Reporting Standards, Hong Kong Accounting Standards ("HKASs") and interpretations issued by Hong Kong Institute of Certified Public Accountants ("HKICPA"), accounting principles generally accepted in Hong Kong and the disclosure requirements of the Hong Kong Companies Ordinance.

The unaudited condensed consolidated financial statements have been prepared under the historical cost convention, as modified for the revaluation of financial instruments which have been measured at fair value.

The accounting policies adopted in preparing the unaudited condensed consolidated financial statements for the period under review are consistent with those followed in the Company's 2024 annual report.

The condensed consolidated financial statements for the six months ended 30 June 2025 are unaudited and have been reviewed by the audit committee of the Company.

3. TURNOVER AND REVENUE

The Group's turnover comprises the invoiced value of merchandise sold net of value-added tax and after allowances for returns and discounts.

	Six months ended 30 June	
	2025	2024
	RMB'000	RMB'000
Turnover		
Sales of medicine	438,869	393,093
Other revenue		
Other income	9,771	30,116
Total revenue for the year	<u>448,640</u>	<u>423,209</u>

4. SEGMENT INFORMATION

The Group has only one business segment which is in the manufacture and distribution of Chinese medicines and pharmaceutical products in the PRC. For the six months ended 30 June 2025, turnover of the Group is generated entirely from sales in the PRC and all identifiable assets of the Group are located in PRC. Accordingly, no business or geographical segmental analysis is prepared for the period.

5. PROFIT FROM OPERATIONS

The Group's profit from operations is arrived at after charging:

	Six months ended 30 June	
	2025	2024
	RMB'000	RMB'000
Depreciation	13,170	10,902
Amortisation of intangible asset	<u>4</u>	<u>4</u>

6. TAXATION

Taxation in the unaudited condensed consolidated income statement represents:

	Six months ended 30 June	
	2025	2024
	RMB'000	RMB'000
PRC income tax	19,856	22,711

The PRC income tax is computed according to the relevant laws and regulations in the PRC. The applicable income tax rate was 15% (2024: 15%).

The Group did not have any significant unprovided deferred taxation for the six months ended 30 June 2025 (2024: Nil).

7. EARNINGS PER SHARE

The calculation of basic earnings per share for the six months ended 30 June 2025 is based on the unaudited profit attributable to shareholders of approximately RMB103,006,000 (2024: RMB104,282,000) and on the weighted average of 560,250,000 (2024: 560,250,000) shares in issue during the period ended 30 June 2025.

There is no diluted earnings per share because there were no dilutive potential shares in existence during the relevant periods.

8. DIVIDENDS

The Board does not recommend the payment of an interim dividend for the six months ended 30 June 2025 (2024: Nil).

9. BEARER BIOLOGICAL ASSETS

	30 June	31 December
	2025	2024
	(Unaudited)	(Audited)
	RMB'000	RMB'000
Ginseng	15,080	15,080

10. PROPERTY, PLANT AND EQUIPMENT

The movements of property, plant and equipment of the Group were:

	30 June 2025 (Unaudited) RMB'000	31 December 2024 (Audited) RMB'000
Net book value, beginning of period/year	251,110	261,559
Additions & Disposals & Transfer	712	10,943
Depreciation & Written back on disposals & Transfer	(13,170)	(21,392)
	<u>238,652</u>	<u>251,110</u>

11. RIGHT-OF-USE ASSETS

The carrying amounts of the Group's right-of-use assets and the movements during the period/year are as follows:

	30 June 2025 (Unaudited) RMB'000	31 December 2024 (Audited) RMB'000
Net book value, beginning of period/year	46,881	48,002
Addition	-	-
Depreciation charge	-	(1,121)
	<u>46,881</u>	<u>46,881</u>

12. CONSTRUCTION IN PROGRESS

	30 June 2025 (Unaudited) RMB'000	31 December 2024 (Audited) RMB'000
Net book value, beginning of period/year	-	4,904
Addition	-	24
Transfer	-	(4,928)
	<u>-</u>	<u>-</u>

13. INTANGIBLE ASSETS

	30 June 2025 (Unaudited) RMB'000	31 December 2024 (Audited) RMB'000
Cost:		
At 1 January	68,167	68,167
Acquisition of subsidiaries	<u>—</u>	<u>—</u>
At 30 June 2025/31 December 2024	<u>68,167</u>	<u>68,167</u>
Accumulated amortisation and impairment loss:		
At 1 January	68,150	68,146
Impairment for the period/year	<u>4</u>	<u>4</u>
At 30 June 2025/31 December 2024	<u>68,154</u>	<u>68,150</u>
Net book value:		
At 30 June 2025/31 December 2024	<u>13</u>	<u>17</u>

Purchased know-how and prescription were all acquired by cash from independent third parties.

14. INVENTORIES

	30 June 2025 (Unaudited) RMB'000	31 December 2024 (Audited) RMB'000
Inventories comprise:		
At cost:		
Raw materials	51,247	32,006
Work in progress	14,804	21,911
Finished goods	34,376	22,424
	<hr/> 100,427 <hr/>	<hr/> 76,341 <hr/>
Less: provision for obsolete and slow-moving inventories	(13,252)	(16,370)
	<hr/> 87,175 <hr/>	<hr/> 59,971 <hr/>

As at 30 June 2025, inventories amounting to approximately RMB87,175,000 (2024: RMB59,971,000) were carried at net realizable value.

15. TRADE RECEIVABLES

Trade receivables are stated at cost less provision for doubtful debts. Provisions for doubtful debts are made based upon the directors' knowledge of the customers, the creditworthiness and settlement history, and the aging of the outstanding trade receivables.

The following is an aged analysis of trade receivables, net of provision for impairment for trade receivables, at the balance sheet dates:

	30 June 2025 (Unaudited) RMB'000	31 December 2024 (Audited) RMB'000
Current	66,962	69,395
31–90 days	81,791	84,763
91–180 days	77,688	80,511
More than 180 days	42,894	44,452
	269,335	279,121

The directors consider the carrying amount of trade receivables approximates their fair value.

16. BANK BORROWINGS

	30 June 2025 (Unaudited) RMB'000	31 December 2024 (Audited) RMB'000
Current		
Bank borrowings – unsecured	72,000	72,000
Non-current		
Bank borrowings – unsecured	–	–
	72,000	72,000

17. TRADE PAYABLES

The following is an aged analysis of trade payables at the balance sheet dates:

	30 June 2025 (Unaudited) RMB'000	31 December 2024 (Audited) RMB'000
Current	6,470	6,223
31–90 days	2,871	2,762
91–180 days	2,977	2,864
More than 180 days	53,746	51,692
	66,064	63,541

Trade payables principally comprise amounts outstanding for trade purchases. The directors consider that the carrying amount of trade payables approximates their fair value.

18. FINANCIAL ASSETS MEASURED AT AMORTISED COST

	30 June 2025 (Unaudited) RMB'000	31 December 2024 (Audited) RMB'000
Term deposits with initial term of over three months and less than one year	209,919	209,919
Term deposits with initial term of over one year	949,037	1,048,737
	1,158,956	1,258,656

19. SHARE CAPITAL

	30 June 2025		31 December 2024	
	Number of shares	(Unaudited) RMB'000	Number of shares	(Audited) RMB'000
Domestic shares of RMB0.10 each	387,750,000	38,775	387,750,000	38,775
H shares of RMB0.10 each	172,500,000	17,250	172,500,000	17,250
	<u>560,250,000</u>	<u>56,025</u>	<u>560,250,000</u>	<u>56,025</u>

20. CAPITAL COMMITMENTS

As at 30 June 2025, the Group had capital commitments contracted for but not provided for in respect of the following:

	30 June 2025 (Unaudited) RMB'000	31 December 2024 (Audited) RMB'000
Acquisition of intangible assets	-	-
Acquisition of property, plant and equipment	-	-
	<u>-</u>	<u>-</u>

MANAGEMENT DISCUSSION AND ANALYSIS

OPERATING RESULTS

For the six months ended 30 June 2025, the Group recorded a turnover of approximately RMB438,869,000, representing an increase of 11.6% from RMB393,093,000 for the corresponding period in 2024. Profit attributable to shareholders for the six months ended 30 June 2025 was RMB103,006,000, representing a decrease of RMB1,276,000 from RMB104,282,000 for the corresponding period in 2024.

The gross profit margin for the six months ended 30 June 2025 was approximately 82.4% representing an increase as compared to the period ended 30 June 2024. The Board believes that this is due to the decrease in production and material cost.

The selling expense as a percentage of turnover was 46% in 2025. This represented an increase from 44% when compared to the same period last year. General and administrative expenses increase from RMB44,380,000 for the six months ended 30 June 2024 to RMB44,655,000 for the same period in 2025.

BUSINESS REVIEW

Production facilities

Small Volume Injection Workshop II of the Company passed the GMP compliance inspection and put into operation to increase production capacity of the Company during the year.

An automatic packaging line system and blister pack visual inspection machine were added in the Solid Pharmacy Workshop I, improving product quality and production efficiency.

New extraction equipment was added in the Traditional Chinese Medicine Extraction Workshop II, expanding production capacity and range.

Thioctic Acid Injection, Furosemide Injection, Urapidil Hydrochloride Injection, and Levocarnitine API obtained registration approvals and have been put into commercial production, enriching the Company's product portfolio and specifications.

LIQUIDITY AND FINANCIAL RESOURCES

The Group has maintained a sound financial position during this period. For the six months ended 30 June 2025, the Group's primary source of funds was cash from the operating activities. As at 30 June 2025, the Group had cash and bank balances and consolidated net asset value of approximately RMB485,117,000 and RMB1,732,620,000 respectively.

For the six months ended 30 June 2025, the Group mainly generated revenue and incurred costs in Hong Kong dollars and Renminbi. The Directors consider the impact on foreign exchange exposure of the Group is minimal.

As at 30 June 2025, the Group had no material contingent liabilities.

GEARING RATIO

As at 30 June 2025, the Group had short-term bank borrowings of RMB72,000,000 (2024: RMB72,000,000) and a gearing ratio of approximately 4.16%. The calculation of the gearing ratio was based on the short-term bank loans and shareholders' equity as at 30 June 2025.

CAPITAL COMMITMENTS

Details of the capital commitments of the Company as at 30 June 2025 are set out in note 20 to the financial statement.

CAPITAL STRUCTURE

During the six months ended 30 June 2025, there was no change in the Company's share capital. As at 30 June 2025, the Group's operations were financed mainly by shareholders' equity. The Group will continue to adopt its treasury policy of placing the Group's cash and cash equivalents in interest bearing deposits, and to fund the operation with internal resources.

FUTURE PROSPECTS

There has been an increase in the Group's turnover as compared with the same period last year.

The Directors would like to take this opportunity to express their gratitude to the management and staff for their dedication and contribution to the Group, and to thank our fellow business partners and equity holders for their continuing support. The Directors will endeavor to explore every potential opportunity for business growth, creating a promising future and successful results in the years ahead.

DIRECTORS' INTERESTS IN SHARES

At 30 June 2025, the interests and short positions of the Directors, supervisors and chief executives of the Company in the shares, underlying shares and debentures of the Company and its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (the "SFO") as recorded in the register required to be kept under Section 352 of the SFO or as otherwise notified to the Company and the Stock Exchange of Hong Kong Limited (the "Stock Exchange") pursuant to the minimum standards of dealing by directors as referred to in Rule 5.46 to 5.67 of the GEM Listing Rules were as follows:

Long positions in shares

Director	Type of Interests	Capacity	Number of Domestic Shares	Percentage of Domestic Shares	Percentage of total registered Share Capital
Mr. Zhang Hong	Personal	Beneficial owner	101,937,000	26.29%	18.19%
Mr. Zhang Xiao Guang	Personal	Beneficial owner	42,315,000	10.91%	7.55%
Mr. Xu Xiang Fu	Personal	Beneficial owner	5,227,000	1.348%	0.933%
Mr. Wu Guo Wen	Personal	Beneficial owner	900,000	0.232%	0.161%

Save as disclosed above, as at 30 June 2025, none of the Directors, supervisors and chief executives of the Company has any interests and short positions in the shares, underlying shares and debentures of the Company and its associated corporations (within the meaning of Part XV of the SFO) as recorded in the register required to be kept under Section 352 of the SFO or as otherwise notified to the Company and the Stock Exchange pursuant to the minimum standards of dealing by directors as referred to in Rule 5.46 to 5.67 of the GEM Listing Rules.

DIRECTORS' RIGHTS TO ACQUIRE SHARES

Apart from as disclosed under the headings "Directors' interests in shares" above, at no time during the period were rights to acquire benefits by means of the acquisition of shares in or debentures of the Company granted to any director and chief executives or their respective spouses or children under 18 years of age, or were any such rights exercised by them; or was the Company, its holding company, or any of its subsidiaries a party to any arrangement to enable the directors, supervisors and chief executives to acquire such rights in any other body corporate.

INTERESTS DISCLOSEABLE UNDER THE SFO AND SUBSTANTIAL SHAREHOLDERS

As at 30 June 2025, the following persons (other than the Directors, supervisors and chief executives of the Company) had interests and short positions in the shares and underlying shares of the Company as recorded in the register required to be kept under Section 336 of the SFO.

Long positions in shares

Name of shareholder	Capacity/Nature of Interest	Number of Domestic Shares	Percentage of Domestic Shares	Percentage of total registered Share Capital
Huinan County SAB (Note)	Beneficial owner	81,975,000	21.14%	14.63%

Note: Apart from the equity interest in the Company, Huinan County SAB does not have any direct or indirect interest in the Company, including representation in the Board of Directors.

Save as disclosed above, as at 30 June 2025, the Directors were not aware of any other person (other than the Directors, supervisors and chief executives of the Company) who had interests and short positions in the shares and underlying shares of the Company as recorded in the register required to be kept under Section 336 of the SFO.

Long positions in H shares

Name of shareholder	Capacity	Number of H Shares	Percentage of H Shares	Percentage of total registered Share Capital
Chen Jingwei	Beneficial owner	29,520,000	17.11%	5.269%
Shen Qianzhen	Beneficial owner	13,996,000	8.11%	2.498%

COMPETING INTEREST

During the period under review, none of the Directors, the management shareholders, the significant shareholders or the substantial shareholders (as defined in the GEM Listing Rules) of the Company had any interest in a business, which competes or may compete with the business of the Group.

CODE OF CONDUCT REGARDING SECURITIES TRANSACTIONS BY DIRECTORS

During the six months ended 30 June 2025, the Company has adopted a code of conduct regarding securities transactions by directors on terms no less than the required standard of dealings as set out in Rules 5.48 to 5.67 of the GEM Listing Rules. The Company has also made specific enquiry of all Directors and the Company was not aware of any non-compliance with the required standard of dealings and its code of conduct regarding securities transactions by Directors.

BOARD PRACTICES AND PROCEDURES

During the period under review, the Company had not fully complied with the board practices and procedures as set out in Rules 5.34 of the GEM Listing Rules in respect of the Code on Corporate Governance Practices (the "CCGP"). The main deviations from the code provision set out in the CCGP were as follows:

Under the code provision A.2.1, the roles of chairman and chief executive officer should be separate and should not be performed by the same individual. Mr. Zhang Hong assumes the role of both the chairman and the chief executive officer of the Company. The Board is of the view that this has not compromised accountability and independent decision making for the following reasons:

- the Audit Committee composes exclusively of independent non-executive directors;
- the independent directors have free and direct access to the Company's external auditors and independent professional advice when considered necessary.

Mr. Zhang Hong, the chairman, is a substantial shareholder of the Company and has considerable industry experience. He is motivated to contribute to the growth and profitability of the Group. The Board is of the view that it is in the best interests of the Group to have an executive chairman so that the Board can have the benefit of a chairman who is knowledgeable about the business of the Group and is most capable to guide discussions and brief the Board in a timely manner on pertinent issues and developments to facilitate open dialogue between the Board and the management.

AUDIT COMMITTEE

The Company set up an audit committee (the “Committee”) on 24 May 2001 with written terms of reference in compliance with the requirements as set out in Rules 5.28 and 5.29 of the GEM Listing Rules. The audit committee comprise three independent non executive directors, namely Gao Qi Pin, Bai Jun Gui and Tian Jie, Gao Qi Pin is the Chairman of the audit committee. The primary duties of the Committee are to review and provide supervision over the financial reporting procedures and internal control system of the Group.

The committee has reviewed with the management the accounting principles and practices adopted by the Group and discussed internal controls and financial reporting matters, including a review of the unaudited results of the Group for the period ended 30 June 2025.

EMPLOYEES AND REMUNERATION POLICIES

As at 30 June 2025, the Group had 798 employees and has employed some temporary sales persons (30 June 2024: 678 employees). Remuneration is determined by reference to market terms and the performance, qualifications and experience of individual employee. Discretionary bonuses based on individual performance will be paid to employees as recognition of and reward for their contribution. Other benefits include contributions to retirement scheme and medical scheme.

PURCHASE, REDEMPTION OR SALE OF LISTED SECURITIES

During the six months ended 30 June 2025, neither the Company nor its subsidiaries purchased, sold or redeemed any of the Company’s listed shares.

By order of the Board
Jilin Province Huinan Changlong Bio-pharmacy Company Limited
Zhang Hong
Chairman

Jilin, the PRC
14 August 2025

As at the date of this report, the Board comprises six executive directors, being Zhang Hong, Zhang Xiao Guang, Zhao Bao Gang, Wu Guo Wen, Zhang Yi and Xu Xiang Fu and three independent non-executive directors, being Gao Qi Pin, Bai Jun Gui and Tian Jie.

This report will remain on the Stock Exchange website at <http://www.hkexnews.hk> on the “Latest Company Announcements” page for 7 days from the day of its posting.